IceCure Medical (TASE:ICCM) - Hisse Senedi Fiyatı, Haberler ve Analizler

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ICCM Stoklara Genel Bakış

A commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. Daha fazla detay

ICCM temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 93.7% daha düşük bir oranda işlem görüyor

Gelirin yılda 47.49% oranında artması öngörülüyor

Risk Analizi

1 yıldan az nakit akışı var

Anlamlı bir piyasa değeri yok ( ₪194M )

Hissedarlar geçen yıl sulandırıldı

Anlamlı bir geliri yok ( $3M )

+ 1 daha fazla risk

IceCure Medical Ltd Rakipler

BrainsWay

TASE:BWAY

₪695.1m

Pulsenmore

TASE:PULS

₪147.6m

SofWave Medical

TASE:SOFW

₪621.4m

Bio-View

TASE:BIOV

₪32.3m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti IceCure Medical
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	₪4.25
52 Haftanın En Yüksek Seviyesi	₪14.97
52 Haftanın En Düşük Seviyesi	₪3.34
Beta	1.6
11 Aylık Değişim	3.71%
3 Aylık Değişim	-11.91%
1 Yıllık Değişim	-27.13%
33 Yıllık Değişim	-16.00%
5 Yıllık Değişim	-33.86%
Halka arzdan bu yana değişim	-99.33%

Son Haberler & Güncellemeler

Will IceCure Medical (TLV:ICCM) Spend Its Cash Wisely?

Jul 13

Recent updates

Hissedar Getirileri

	ICCM	IL Medical Equipment	IL Pazar
7D	-3.6%	1.8%	1.6%
1Y	-27.1%	3.4%	25.8%

Getiri vs. Endüstri: ICCM geçen yıl % 3.4 oranında getiri sağlayan IL Medical Equipment sektörünü aştı.

Getiri vs Piyasa: ICCM geçen yıl % 25.8 oranında getiri sağlayan IL Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is ICCM's price volatile compared to industry and market?
ICCM volatility
ICCM Average Weekly Movement	5.0%
Medical Equipment Industry Average Movement	5.8%
Market Average Movement	4.1%
10% most volatile stocks in IL Market	7.3%
10% least volatile stocks in IL Market	2.9%

İstikrarlı Hisse Senedi Fiyatı: ICCM son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: ICCM 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 43% dan 5% a düştü.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2006	69	Eyal Shamir	www.icecure-medical.com

IceCure Medical Ltd Temel Bilgiler Özeti

IceCure Medical'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ICCM temel i̇stati̇sti̇kler
Piyasa değeri	₪194.08m
Kazançlar(TTM)	-₪59.62m
Gelir(TTM)	₪11.15m

17.4x

P/S Oranı

-3.3x

F/K Oranı

ICCM aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ICCM gelir tablosu (TTM)
Gelir	US$3.05m
Gelir Maliyeti	US$1.72m
Brüt Kâr	US$1.33m
Diğer Giderler	US$17.63m
Kazançlar	-US$16.30m

Son Raporlanan Kazançlar

Mar 31, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.36
Brüt Marj	43.67%
Net Kâr Marjı	-534.74%
Borç/Özkaynak Oranı	0%

ICCM uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

This company listing is no longer active

ICCM Stoklara Genel Bakış

Ödüller

Risk Analizi

IceCure Medical Ltd Rakipler

TASE:BWAY

₪695.1m

TASE:PULS

₪147.6m

TASE:SOFW

₪621.4m

TASE:BIOV

₪32.3m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Will IceCure Medical (TLV:ICCM) Spend Its Cash Wisely?

New major risk - Financial position

New major risk - Revenue and earnings growth

IceCure Medical Ltd to Report Q1, 2023 Results on May 22, 2023

Insufficient new directors

Full year 2022 earnings released: US$0.46 loss per share (vs US$0.35 loss in FY 2021)

Recent updates

Will IceCure Medical (TLV:ICCM) Spend Its Cash Wisely?

New major risk - Financial position

New major risk - Revenue and earnings growth

IceCure Medical Ltd to Report Q1, 2023 Results on May 22, 2023

Insufficient new directors

Full year 2022 earnings released: US$0.46 loss per share (vs US$0.35 loss in FY 2021)

Here's Why We're Watching IceCure Medical's (TLV:ICCM) Cash Burn Situation

IceCure Medical Ltd Receives Notice of Allowance from the U.S. Patent and Trademark Office for Its Patent Application Titled Cryogen Pump

IceCure Medical Ltd Receives Notice of Patent Allowance in Japan for A Novel Cryogenic Pump for Its Next-Generation Cryoablation Systems

IceCure Medical Ltd Announces Interim Results from the ICESECRET Study for the Treatment of Patients with Small Renal Masses

IceCure Appoints Vincent Chun Hung Chan to Serve as an Independent Director on its Board of Directors

Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.091 loss in 3Q 2021)

IceCure Medical Ltd to Report Nine Months, 2022 Results on Dec 05, 2022

IceCure's ProSense® Achieves Significant Milestone in Medicare Coverage of Breast Cancer Procedures

IceCure Medical Ltd. Files De Novo Classification Request with the FDA for Marketing Authorization of ProSense with Breakthrough Indication: Early-Stage Low-Risk Breast Cancer Patients at High Risk to Surgery

Are Investors Undervaluing IceCure Medical Ltd (TLV:ICCM) By 29%?

IceCure Medical Ltd Submits Regulatory Filing in Vietnam for Approval of Prosense®

Second quarter 2022 earnings released

IceCure Medical Ltd to Report Q2, 2022 Results on Aug 15, 2022

IceCure Medical Ltd Announces Regulatory Filing Submission for Approval of ProSense® in Canada for Indications Including Ablation of Benign and Malignant Breast Tumors

IceCure Medical Ltd to Report Q1, 2022 Results on May 18, 2022

Full year 2021 earnings released: US$0.35 loss per share (vs US$0.27 loss in FY 2020)

Is IceCure Medical Ltd (TLV:ICCM) Potentially Undervalued?

IceCure Medical Ltd, Annual General Meeting, Mar 03, 2022

Icecure Medical Ltd Medical Receives Notice of Intention to Grant A European Patent Covering Its Cryogenic Pump

Is IceCure Medical (TLV:ICCM) In A Good Position To Deliver On Growth Plans?

IceCure Medical's Interim Results of the ICE3 Clinical Trial for Early-Stage Breast Cancer Cryoablation featured at the 2021 Annual Meeting of the Radiological Society of North America

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Icecure Medical Announces First Peer Reviewed Publication for the 3-Year Interim Analysis of the Ice3 Trial on Cryoablation of Low-Risk, Early-Stage Breast Cancer

Icecure Medical Ordinary Shares Deleted from Other OTC

IceCure Medical Ltd. Announces Positive Interim Results from ICE3 Clinical Trial for Breast Cancer Treatment by Freezing with the ProSense® Cryoablation System Presented at the 2021 ASBrS Meeting

Full year 2020 earnings released: ₪0.11 loss per share (vs ₪0.15 loss in FY 2019)

IceCure Signs Exclusive Distribution Agreement with Rise General Trading, LCC, Expanding Market Reach Across the Middle East

New 90-day high: ₪1.48

New 90-day high: ₪0.70

IceCure Medical Ltd Inks Expanded Distribution Agreement with Terumo Corporation for Thailand

New 90-day high: ₪0.72

IceCure Medical Ltd Expands Strategic Collaboration with Terumo Corporation, New Commercial Distribution Agreement Potentially Valued at over $7.0 Million

IceCure Medical Ltd has completed a Follow-on Equity Offering in the amount of ILS 20.7 million.

New 90-day low - ₪0.52

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

IceCure Medical Ltd Temel Bilgiler Özeti

17.4x

-3.3x

Kazanç ve Gelir